Zobrazeno 1 - 10
of 18
pro vyhledávání: '"Veronika Blum"'
Autor:
Veronika Blum, Vanghelita Andrei, Baptiste Ameline, Silvia Hofer, Bruno Fuchs, Klaus Strobel, Anna Allemann, Beata Bode, Daniel Baumhoer
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
Mesenchymal chondrosarcoma is a rare and aggressive sarcoma subtype with high risk for distant metastases and poor prognosis. Currently NCCN- and ESMO-Guidelines recommend using Ewing sarcoma protocols as standard treatment. Nevertheless, in localize
Externí odkaz:
https://doaj.org/article/b91aeeda9dcb480d83a630b4844bd781
Autor:
Karin Ribi, Beat Thürlimann, Corinne Schär, Daniel Dietrich, Richard Cathomas, Ursina Zürrer-Härdi, Thomas von Briel, Sandro Anchisi, Pierre Bohanes, Veronika Blum, Philippe von Burg, Meinrad Mannhart, Clemens B. Caspar, Roger von Moos, Michael Mark
Publikováno v:
BMC Cancer, Vol 21, Iss 1, Pp 1-9 (2021)
Abstract Background Bone-targeted agents (BTAs) are widely used in the management of patients with bone metastases from solid tumors. Knowledge of the impact of their routine care use on patient-reported pain and bone pain-related quality of life (Qo
Externí odkaz:
https://doaj.org/article/2f4e37bedf8d49deba6179a01a81e7f8
Autor:
Silvia Hofer, Leopold Hentschel, Stephan Richter, Veronika Blum, Michael Kramer, Bernd Kasper, Christoph Riese, Markus K. Schuler
Publikováno v:
Cancers, Vol 15, Iss 4, p 1233 (2023)
The PazoQoL prospective, randomized, controlled, multicenter study was designed to continuously assess global health related quality of life (HRQoL) during treatment with pazopanib or physician-preferred chemotherapy over a 9-week period. The questio
Externí odkaz:
https://doaj.org/article/4e1181b0395c44a39c80091a690a7e14
Autor:
Michael Mark, Beat Thürlimann, Karin Ribi, Corinne Schär, Daniel Dietrich, Richard Cathomas, Ursina Zürrer-Härdi, Thomas von Briel, Sandro Anchisi, Pierre Bohanes, Veronika Blum, Philipp von Burg, Meinrad Mannhart, Clemens B Caspar, Roger von Moos
Publikováno v:
Journal of Bone Oncology, Vol 21, Iss , Pp - (2020)
Background: Bone-targeted agents (BTAs) are widely used in the management of patients with bone metastases from solid tumors, but knowledge of their routine care use and the therapeutic implications remains limited. This non-interventional study aime
Externí odkaz:
https://doaj.org/article/0e77d4190fbb434184b3402e30ef62de
Autor:
Christian Rothermundt, Dimosthenis Andreou, Jean-Yves Blay, Thomas Brodowicz, Ingrid M.E. Desar, Palma Dileo, Hans Gelderblom, Rick Haas, Jens Jakob, Robin L. Jones, Ian Judson, Wolfgang G. Kunz, Berndadette Liegl-Atzwanger, Lars H. Lindner, Christina Messiou, Aisha B. Miah, Peter Reichardt, Joanna Szkandera, Winette T.A. van der Graaf, Winan J. van Houdt, Eva Wardelmann, Silvia Hofer, Thomas Barth, Sebastian Bauer, Veronika Blum, Beata Bode, Sylvie Bonvalot, Judith Bovee, Petra Braam, Jean Martin Broto, Angelo Dei Tos, Dominik Denschlag, Ingrid Desar, Antonia Digklia, Uta Dirksen, Thomas Douchy, Florence Duffaud, Mikael Eriksson, Stefan Fröhling, Alessandro Gronchi, Jenrik Hardes, Wolfgang Hartmann, Peter Hohenberger, Daphne Hompes, Paul Huang, Antoine Italiano, Robin Jones, Günter Köhler, Attila Kollàr, Fatime Krasniqi, Stijn Krol, Wolfgang Kunz, Franel Le Grange, Cécile Le Pechoux, Alexandre LeCesne, Andreas Leithner, Bernadette Liegl-Atzwanger, Lars Lindner, Gunhild Mechtersheimer, Aisha Miah, Daniel Pink, Cleo Romagosa, Piotr Rutkowski, Akmel Safwat, Claudia Sangalli, Khin Thway, Per-Ulf Tunn, Winette Van der Graaf, Winan Van Houdt, Ralph Zachariah, Sander Botter, Thomas Cerny
Publikováno v:
European Journal of Cancer, 180, pp. 158-179
European Journal of Cancer, 180, 158-179
European Journal of Cancer, 180, 158-179
Owing to the rarity and heterogeneity in biology and presentation, there are multiple areas in the diagnosis, treatment and follow-up of soft tissue sarcoma (STS), with no, low-level or conflicting evidence.During the first Consensus Conference on th
Autor:
Magdalena Hecz, Stefan Aebi, Beat Mller, Thilo Zander, Christian Riklin, Ralph Winterhalder, Daniela Weiler, Kristin Zeidler, Veronika Blum, Philipp Niederberger, Benedetta Campana, Oliver Gautschi
Publikováno v:
Forum Médical Suisse ‒ Swiss Medical Forum.
Autor:
Magdalena Hecz, Stefan Aebi, Beat Mller, Thilo Zander, Christian Riklin, Ralph Winterhalder, Daniela Weiler, Kristin Zeidler, Veronika Blum, Philipp Niederberger, Benedetta Campana, Oliver Gautschi
Publikováno v:
Swiss Medical Forum ‒ Schweizerisches Medizin-Forum.
Autor:
Veronika Blum, Vanghelita Andrei, Baptiste Ameline, Silvia Hofer, Bruno Fuchs, Klaus Strobel, Anna Allemann, Beata Bode, Daniel Baumhoer
Background: Mesenchymal chondrosarcoma is a rare and aggressive sarcoma subtype with high risk for distant metastases and poor prognosis. Currently NCCN- and ESMO-Guidelines recommend using Ewing sarcoma protocols as standard treatment. Nevertheless,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::66da690b78ae590ac88aeafa59554e54
https://doi.org/10.21203/rs.3.rs-2057200/v1
https://doi.org/10.21203/rs.3.rs-2057200/v1
Autor:
Luciano Wannesson, Wolfram Jochum, H. Bouchaab, David König, Wolf-Dieter Janthur, Patrizia Frösch, Martin Früh, Alex Friedlaender, Sacha I. Rothschild, Laetitia A. Mauti, Alfredo Addeo, Izadora Demmer, Sämi Schär, Sabine Schmid, Christian Britschgi, Veronika Blum
Publikováno v:
Cancer Immunology, Immunotherapy. 69:1605-1613
Early clinical trials showed promising outcomes with immune-checkpoint inhibitors (ICI) in a subset of patients with relapsed small-cell lung carcinoma (SCLC). The aim of this retrospective analysis was to assess the efficacy and safety of ICI for re
Autor:
Armita Bahrami, David R. Lucas, Mari F.C.M. van den Hout, Judith V.M.G. Bovée, Steven D. Billings, Holger Moch, Vaiyapuri P. Sumathi, Gabriel Oaxaca, Sébastien Aubert, Veronika Blum, Marta Barisella, Josephine K Dermawan, Elizabeth M Azzato, Brendan C. Dickson, Raf Sciot, Akihiko Yoshida, Daniel Baumhoer, Beata Bode, Scott W Aesif, Brian P. Rubin, Karen Fritchie, Alberto Righi
Publikováno v:
Modern Pathology, 34(12), 2211-2221. SPRINGERNATURE
Modern Pathology, 34(12), 2211-2221. Nature Publishing Group
Modern Pathology, 34(12), 2211-2221. Nature Publishing Group
YAP1-TFE3-fused hemangioendothelioma is an extremely rare malignant vascular tumor. We present the largest multi-institutional clinicopathologic study of YAP1-TFE3-fused hemangioendothelioma to date. The 24 cases of YAP1-TFE3-fused hemangioendothelio